OncoMatch/Clinical Trials/NCT06587061

HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Is NCT06587061 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies HRS-4642+AG for pancreatic cancer.

Phase 2RecruitingRuijin HospitalNCT06587061Data as of May 2026

Treatment: HRS-4642+AG — To evaluate the safety and efficacy of HRS-4642 in Combination With AG for Neoadjuvant and Adjuvant Treatment of Pancreatic Cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Pancreatic Cancer

Disease stage

Required: Stage RESECTABLE PANCREATIC CANCER (INCLUDING HIGH-RISK RESECTABLE), BORDERLINE RESECTABLE PANCREATIC CANCER (NCCN guidelines)

Excluded: Stage DISTANT METASTATIC

Imaging evaluation met the NCCN guidelines definition of resectable pancreatic cancer (including high-risk resectable) and borderline resectable pancreatic cancer. the presence of distant metastatic lesions diagnosed by imaging [excluded]

Performance status

ECOG 0–1(Restricted strenuous activity)

Prior therapy

No prior treatment (treatment-naive required)

Max 0 prior lines

Cannot have received: anti-tumor therapy

Previously received any anti-tumor therapy

Lab requirements

Blood counts

adequate marrow function

Kidney function

adequate organ function

Liver function

adequate organ function

Adequate marrow and organ function

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify